8-KLeadership ChangesExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Aug 23, 2016)

Filed August 23, 2016For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) announced the appointment of Kelly A. Kramer to its Board of Directors, effective August 19, 2016. Ms. Kramer will also serve on the Audit Committee. Her appointment is a procedural disclosure and does not involve any undisclosed arrangements or related party transactions. Investors should note that Ms. Kramer's compensation for her board service includes a pro-rated equity grant of stock options and restricted stock units, along with a pro-rated cash retainer. This appointment is primarily a governance update, with no immediate material impact on Gilead's operational or financial performance. The details of the compensation are consistent with typical director compensation structures, and further information on the company's equity incentive plan and director compensation practices can be found in previously filed public documents. The inclusion of a press release as an exhibit indicates the company's intent to publicly communicate this board change.

Key Highlights

  • 1Kelly A. Kramer appointed to Gilead's Board of Directors, effective August 19, 2016.
  • 2Ms. Kramer will serve as a member of the Board's Audit Committee.
  • 3No undisclosed arrangements or related party transactions involving Ms. Kramer were reported.
  • 4Ms. Kramer will receive pro-rated compensation for her director services.
  • 5Compensation includes a pro-rated equity grant (stock options and RSUs) and a pro-rated cash retainer.
  • 6Details of director compensation and equity plans are available in prior SEC filings.
  • 7A press release announcing the appointment is attached as an exhibit.

Frequently Asked Questions

The filing does not provide details on Ms. Kramer's specific background or qualifications. However, her appointment to the Audit Committee suggests relevant experience in finance, accounting, or governance. Investors may refer to the attached press release (Exhibit 99.1) for potential additional information not included in this 8-K filing.

The financial impact of Ms. Kramer's appointment itself is minimal. The compensation described (equity grants and cash retainer) is standard for a new board member and is part of the company's established director compensation program. It does not represent a significant new expenditure or alter Gilead's overall financial outlook.

More detailed information about Gilead's 2004 Equity Incentive Plan and compensation practices for non-employee directors can be found in the company's Definitive Proxy Statement filed on March 28, 2016, and in the 2004 Equity Incentive Plan exhibit filed on May 13, 2013. The 2005 Deferred Compensation Plan is in the Annual Report on Form 10-K filed February 27, 2009.